TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05847179: Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

Sponsor: PRG Science & Technology Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,988,000

Rescue Site Savings

+$1,958,800

Unlock Full NCT05847179 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05847179 Rescue Dossier →